

# IMMUNOTOXICITY OF DIOXINS AND POPS

## 2,3,7,8-TETRACHLORODIBENZO-*P*-DIOXIN (TCDD) STIMULATES THE POSITIVE SELECTION OF CD4<sup>+</sup>CD8<sup>+</sup> THYMOCYTES THROUGH THE ACTIVATION OF MKK1/2 AND PKC

Shin-ichi Tsukumo, Chiharu Tohyama and Keiko Nohara

Environmental Health Sciences Division, National Institute for Environmental Studies, Onogawa, Tsukuba, Ibaraki, 305-0053, Japan  
CREST, JST (Japan Science and Technology), Kawaguchi, Saitama, 332-0012, Japan

### Introduction

It has been reported that TCDD has a profound effect on thymocytes in mice, such as inhibition of proliferation, stimulation of positive selection, and skewing toward CD4<sup>+</sup>CD8<sup>+</sup> cells<sup>1-3</sup>.

The mitogen-activated protein kinase (MAPK) pathways including ras, raf-1 and MKK1/2 have been generally implicated in differentiation and proliferation of cells. This pathway is also necessary for positive selection of thymocytes. Dominant negative forms of Ras, Raf-1, or MKK1 inhibited positive selection. Constitutive expression of active Raf-1 enhanced positive selection, confirming the importance of this pathway during T cell maturation<sup>4,6</sup>.

T cell receptor ligation induces phosphatidylinositol-4,5-bisphosphate hydrolysis through the activation of phospholipase C $\gamma$ 1 to form two products: inositol 1,4,5-triphosphate and diacylglycerol. A major role of inositol 1,4,5-triphosphate is the elevation of intracellular calcium levels. Diacylglycerol, on the other hand, is involved in the activation of protein kinase C (PKC). PKC is suggested to be involved in positive and negative selection of thymocytes<sup>7,8</sup>, while other worker reported that the inhibition of PKC had no effect on either positive or negative selection<sup>9</sup>.

In this reports, we examined the role of MKK1/2 and PKC in the TCDD-stimulated positive selection of thymocytes using specific inhibitors of these kinases.

### Methods and Materials

**Chemicals:** 2,3,7,8-TCDD was purchased from Cambridge Isotope Laboratory. The purity was higher than 99.5 %. The solvent DMSO was from E. Merck. U0126, G66976 and PD98059 were from Calbiochem.

**Fetal thymus organ culture:** Lobes of the thymus were randomly collected aseptically from 15.5-day-old C57BL/6N embryos with a precautions measure of avoiding connective tissue. Three lobes were placed on a nitrocellulose filter of 45- $\mu$ m pore size, which was set in a 12-well culture plate with 1 ml culture medium (RPMI 1640 supplemented with 10 % fetal calf serum, 5 x 10<sup>-4</sup> M  $\beta$ -mercaptoethanol, 100 U/ml penicillin and 0.1 mg/ml streptomycin). 2,3,7,8-TCDD dissolved in DMSO was added to a final concentration of 10 nM in 0.05 % DMSO. Control lobes were cultivated in the medium plus DMSO. The thymus lobes were incubated at 37 °C and 5 % CO<sub>2</sub> in a water-saturated atmosphere. Every 3 days, half the culture medium in each well was replaced by fresh medium containing the same concentration of chemicals. On day 1, 2, 6 and 9 single-cell suspensions were prepared by gently homogenizing the thymus lobes in phosphate-buffered saline

# IMMUNOTOXICITY OF DIOXINS AND POPS

(PBS) between slide glasses.

**Flow cytometric staining and analysis:** Portions of thymocytes were stained in a volume of 100 $\mu$ l with titrated amounts of fluorescence-conjugated anti-mouse antibodies, for 30 min on ice in the dark. The following antibodies and reagents were used: phycoerythrin (PE)-conjugated anti-mouse CD4 (clone GK1.5), fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD8 (clone 53-6.7), biotin-conjugated anti-mouse CD3 $\epsilon$  (clone 145-2C11), and streptavidin-APC, all from PharMingen (San Diego, CA).

**Cell permeabilization and Bcl-2 staining:** For Bcl-2 staining, cells were permeabilized as described previously<sup>10</sup>. Briefly, single cell suspensions were stained with anti-mouse Bcl-2 (clone 3F11, PharMingen) in staining buffer (SB, 1 % FCS in PBS) containing 0.03 % saponin. After washing, the cells were incubated with biotinylated goat anti-hamster serum in SB containing saponin. The cells were washed and stained with streptavidin-APC in saponin-containing SB. After washing, cells were stained with anti-CD4 and anti-CD8 mAb in SB without saponin.

## Results and Discussion

On day 6 and 9 after the start of fetal thymus organ culture (FTOC) from gestation day 15.5 fetuses, we observed a significant increase in the expression of CD3, CD69 and Bcl-2 in the CD4<sup>+</sup>CD8<sup>+</sup> thymocytes in the presence of 10 nM TCDD as well as the skewing to CD4<sup>+</sup>CD8<sup>+</sup> cells. Particularly, the up regulation of CD3 was remarkable. The up regulation of these proteins in the CD4<sup>+</sup>CD8<sup>+</sup> cells indicated the enhancement of positive selection by TCDD.

A molecular mechanism by which TCDD stimulates the positive selection is unknown. MKK1/2 is reported to be involved in the differentiation of thymocytes, especially to CD4<sup>+</sup>CD8<sup>-</sup> cells. We added an inhibitor of MKK1/2 (PD98059 or U0126) in the FTOC in the presence of or absence from TCDD to test the role of MAPK signaling pathway in the TCDD-stimulated positive selection. As a result, these inhibitors suppressed the TCDD-stimulated CD3 up-regulation as well as the percentage of CD4<sup>+</sup>CD8<sup>-</sup> cells, but did not suppress the differentiation to CD4<sup>+</sup>CD8<sup>+</sup> cells. These results indicated that TCDD-stimulated positive selection depended on the activation of MKK1/2 as found in the normal differentiation.

In primary-cultured hepatocytes, TCDD was reported to enhance phosphorylation of Shc protein and to stimulate the complex formation of Shc-Grb2-Sos<sup>11</sup>. The complex is thought to activate Ras protein followed by the activation of MAPK pathway. If TCDD enhances phosphorylation of Shc in thymocytes as well, it is thought to stimulate MAPK pathway and positive selection as observed in this study.

Although PKC is essential for the activation initiated by TCR in peripheral T cell, the role of PKC in the differentiation of thymocytes is not clear, which led us to utilize a PKC inhibitor G $\delta$ 6976. We found that G $\delta$ 6976 inhibited the TCDD-stimulated up-regulation of CD3 among CD4<sup>+</sup>CD8<sup>+</sup> cell populations. On the contrary, G $\delta$ 6976 did not have any effects on the population defined by CD4 and CD8. Higher concentration of G $\delta$ 6976 repressed the CD3 expression of CD4<sup>+</sup>CD8<sup>+</sup> cell populations in the absence of TCDD. Therefore, the results indicated that PKC was involved in normal and TCDD-stimulated CD3 expression.

In conclusion, TCDD enhances the CD3 up regulation of CD4<sup>+</sup>CD8<sup>+</sup> double positive thymocytes (i.e. positive selection) through the activation of MKK1/2 and PKC.

# IMMUNOTOXICITY OF DIOXINS AND POPS




Figure 1. The effects of MKK1/2 inhibitor PD98059 on the CD3 expression of CD4<sup>+</sup>CD8<sup>+</sup> thymocytes. Mean fluorescence intensity is indicated in the right-upper corner of each figure.

## Acknowledgments

We thank Ms. Mika Kijima (CREST, JST) for her skillful assistance for FTOC. We also thank Dr. Makoto Iwata (Mitsubishi Kasei Institute of Life Sciences) for his kind guidance and useful discussions for FTOC, and Dr. Hidekazu Fujimaki (NIES) for his critical suggestions.

## References

1. Esser, C., Lai, Z., and Gleichmann, E. (1994) *Exp Clin Immunogenet* 11, 75-85.
2. Kremer, J., Lai, Z. W., and Esser, C. (1995) *Eur J Pharmacol* 293, 413-427.
3. Lai, Z. W., Griem, P., Gleichmann, E., and Esser, C. (1995) *Toxicol Appl Pharmacol* 133, 223-232.
4. Alberola-Ila, J., Forbush, K. A., Seger, R., Krebs, E. G., and Perlmutter, R. M. (1995) *Nature*

## IMMUNOTOXICITY OF DIOXINS AND POPS

373, 620-623.

5. Bommhardt, U., Basson, M. A., Krummrei, U., and Zamoyska, R. (1999) *J Immunol* 163, 715-722.

6. Sebzda, E., Mariathasan, S., Ohteki, T., Jones, R., Bachmann, M. F., and Ohashi, P. S. (1999) *Annu Rev Immunol* 17, 829-874.

7. Nakayama, K., and Nakauchi, H. (1993) *Int Immunol* 5, 419-426.

8. Ohoka, Y., Kuwata, T., Asada, A., Zhao, Y., Mukai, M., and Iwata, M. (1997) *J Immunol* 158, 5707-5716.

9. Anderson, G., Anderson, K. L., Conroy, L. A., Hallam, T. J., Moore, N. C., Owen, J. J., and Jenkinson, E. J. (1995) *J Immunol* 154, 3636-3643.

10. Veis, D. J., Sentman, C. L., Bach, E. A., and Korsmeyer, S. J. (1993) *J Immunol* 151, 2546-2554.

11. Park, R., Kim, D. H., Kim, M. S., So, H. S., Chung, H. T., Kwon, K. B., Ryu, D. G., and Kim, B. R. (1998) *Biochem Biophys Res Commun* 253, 577-581.